AdAlta Gains Financing Flexibility with Premium Options Exercise

AdAlta Ltd (ASX: 1AD) has received $1.9 million of new equity from the exercise of the listed 1ADOA options.

Providing confidence in the company’s operations, the exercise was led by an existing major shareholder at a 20% premium.

The new funds provided give AdAlta enhanced financing flexibility as it advances strategic partnerships.

In April, AdAlta entered a finance facility with New Life Sciences Capital LLC and also existing shareholder Meurs Group, who holds a 12.5% stake.

The largest shareholder is Platinum International Healthcare Fund with 16.5%.

Cash held at the end of March 2024 was $1.5 million.

Technology

AdAlta is a clinical stage drug development company using its proprietary i-body® technology platform to solve challenging drug targeting problems.

The i-body® technology creates a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets.

These include the G-protein coupled receptors (GPCRs) that are implicated in many serious diseases.

i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

Valuation proposition

AdAlta is capped around $13 million, and with estimated cash in the vicinity of $3 million, the enterprise value is in the $10 million region.

The top 5 shareholders hold a 45% stake, and with funds usually long-term holders, this reduces the free float available to purchase on market.

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest